Advertisement

Topics

Grid Therapeutics signs exclusive license agreement to develop novel immuno-oncology antibody

05:15 EDT 23 Aug 2017 | Pharmaceutical Business Review

Grid Therapeutics has signed an exclusive license agreement with Duke University to develop the first human derived antibody as a targeted immunotherapy for cancer.

Original Article: Grid Therapeutics signs exclusive license agreement to develop novel immuno-oncology antibody

NEXT ARTICLE

More From BioPortfolio on "Grid Therapeutics signs exclusive license agreement to develop novel immuno-oncology antibody"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...